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Abstract
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Fatty acid drug discovery (FADD) is defined as the identification of novel, specialized bioactive
mediators that are derived from fatty acids and have precise pharmacological/therapeutic potential.
A number of reports indicate that dietary intake of omega-3 fatty acids and limited intake of
omega-6 promotes overall health benefits. In 1929, Burr and Burr indicated the significant role of
essential fatty acids for survival and functional health of many organs. In reference to specific
dietary benefits of differential omega-3 fatty acids, docosahexaenoic and eicosapentaenoic acids
(DHA and EPA) are transformed to monohydroxy, dihydroxy, trihydroxy, and other complex
mediators during infection, injury, and exercise to resolve inflammation. The presented FADD
approach describes the metabolic transformation of DHA and EPA in response to injury, infection,
and exercise to govern uncontrolled inflammation. Metabolic transformation of DHA and EPA
into a number of pro-resolving molecules exemplifies a novel, inexpensive approach compared to
traditional, expensive drug discovery. DHA and EPA have been recommended for prevention of
cardiovascular disease since 1970. Therefore, the FADD approach is relevant to cardiovascular
disease and resolution of inflammation in many injury models. Future research demands
identification of novel action targets, receptors for biomolecules, mechanism(s), and druginteractions with resolvins in order to maintain homeostasis.
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2. Introduction
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Fatty acids are functionally diverse, caloric energy molecules involved in several cellular
signalling events that are associated with various physiological processes after metabolism
(Zárate et al., 2017). Dietary intake of specific polyunsaturated fatty acids (PUFAs; linolenic
and linoleic acid) protects from a wide range of diseases including heart disease and cancer,
to neurological and metabolic disorders. There are several reports and findings
demonstrating that balanced intake of omega-3 and omega-6 PUFAs provide overall health
benefits. The therapeutic potential of fatty acids primarily relies on their metabolic
intermediates and lipid mediator bioactives. Fatty acid metabolism is largely mediated
through an oxygenation process catalyzed by three classes of enzymes: lipoxygenase (LOX),
cyclooxygenase (COX) and cytochrome P450 (CYP) epoxygenase that results in an array of
fatty acid-derived metabolic lipid mediators (Massey and Nicolaou, 2011). Two major
omega-3 fatty acids, docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), gain
the attention of researchers worldwide to transform into pro-resolving biomolecules,
enabling a novel and inexpensive approach to drug discovery. Recent emerging reports
indicate that DHA- and EPA-derived lipid mediators facilitate resolution of inflammation in
the tissue to protect against cardiac disorders (Mittal et al., 2010). The Fatty Acid Drug
Discovery (FADD) outlook is a novel application of fatty acid-derived lipid mediators for
specific therapeutic implication. Fatty acid metabolic transformation is under the regulation
of LOXs, COXs, and CYP and results in a group of bioactive lipid mediators with proinflammatory and anti-inflammatory activities (Wanga et al., 2014). The catalyzing enzyme
interaction of fatty acid-based precursors and oxygenation results in formation of specialized
pro-resolving mediators (SPM; AA-Lipoxin, EPA- E series Resolvins and DHA- D series
Resolvins and Protectins and Maresins) and pro-inflammatory lipid mediators (LTs and
PGs) (Serhan, 2014). The resolvins, both D- and E-series, are reported as key lipid mediators
in the diverse resolution of the inflammatory process. Mass spectrometry-based analytical
technology allows the identification of selective metabolic transformations of fatty acids,
which is essential for SPM biosynthesis utilizing dietary PUFAs (DHA and EPA) and their
intermediates to facilitate resolution of inflammation (Zhang, Guodong et al., 2014). In the
presented review, we address the differential applications of lipid mediators in the course
and resolution of inflammation with a model of drug discovery, particularly for fatty acidderived molecules.

3. Primer on drug discovery
Author Manuscript

The cost of traditional drug discovery escalates each year, now reaching more than 2.6
billion dollars, including the price of failure and the opportunity cost (Mullard, 2014).
Moreover, medicine without adverse effects is rare due to complex human metabolism, dietdrug interaction, and disease pathology. Hiring chemists to perform an array of drug
discovery steps, conducting post-marketing surveillance, and monitoring adverse effects on a
large number of patients contributes significantly to the cost of the new drug. An alternative
route that reduces the enormous cost of the drug discovery is recycling or repurposing
known molecules for different uses (Cressey, 2011). However, this approach to control
obesity, for example, is ineffective without consideration of the extensive evolution of
Biotechnol Adv. Author manuscript; available in PMC 2019 July 01.
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human metabolism and progressive sedentary lifestyle. Thus, to overcome the failure in drug
discovery and to develop novel drugs for metabolic dysregulation, alternative approaches are
urgently needed. The human metabolism evolves with time and works non-stop from birth to
death to adapt to injury, infection, stress (e.g., exercise, change in circadian rhythm, etc.),
and climate change (different seasons/year). The body responds to injury and stress with the
adaptive response and forms differential molecules using the available substrate. Therefore,
precise chemical knowledge of substrate-enzyme interaction (protein, fat, carbohydrate and
amino acid) and information on degradation products will provide unique bioactive options.
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In the presented summary, we review two omega-3 fatty acids, DHA and EPA, which form
endogenous specialized biomolecules that resolve inflammation in response to injury,
infection, and exercise. The pharmaceutical industry is using the template of these molecules
to develop novel medicine in the form of lipids, short and long acting peptides, proteins, or
gases (hydrogen sulphide, carbon monoxide, and nitric oxide) (Corminboeuf and Leroy,
2015; Perretti et al., 2015; Serhan, 2014). We demonstrate the process of novel drug
development using traditional drug discovery, emphasizing specifically the quality, safety,
and efficacy before reaching the market in Figure 1. Through the examples of DHA and
EPA, the second half of the figure suggests that studying the absorption, distribution,
metabolism, and excretion of any diet/nutrient will allow us to harness the benefit of reverse
pharmacology (Patwardhan and Vaidya, 2010) (Figure 1). This process, during which
previously identified molecular targets are used as drug candidates for intervention in
pathological conditions, is an efficient approach to hone in on specific drug candidates faster
than the classical pharmacology approach. For example, in reverse pharmacology, a novel
molecule is identified, and a genomic study takes place. Compounds are then screened,
identified, and functional studies are performed to target a specific drug candidate. This is
opposite from the traditional pharmacologic process, which first attempts to understand the
pharmacokinetics and functional activity of a compound, then identifies a drug candidate,
and finally studies the genomics and molecular mechanisms associated with the drug
(Takenaka, 2001). Of course, reverse pharmacology will not be the direct solution for
neglected, orphan, and genetic diseases, but extensive knowledge of metabolism from birth
to aging will provide a strategy for adapting necessary steps to treat a patient for many
diseases. For the alternative drug discovery route, some governing bodies, such as the UK
Medical Research Council, US National Institutes of Health, and the National Center for
Advancing Translational Sciences, are making progress in collaborating with academic
institutions to produce more basic discoveries for the advancement of medical therapeutic
programs.

Author Manuscript

4. Primer on fatty acids, nutrition, and obesity
The global prevalence of obesity in men and women is directly linked to lack of healthy diet,
practices of imbalanced lifestyle (disturbed sleep and wake cycle), and a number of obesityrelated chronic diseases that include cardiovascular events (Djousse et al., 2012; Flegal et al.,
2012; Gregg and Shaw, 2017; Held et al., 2012; Sowers, 2003). There are more than 100
factors that contribute to the development of obesity. Recent genomic data indicates that
individual responses to fat molecules are much more complex than expected (Locke et al.,
2015). Therefore, it is advisable to follow healthy eating practices by limiting emphasis on
Biotechnol Adv. Author manuscript; available in PMC 2019 July 01.
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high and low fat/carbohydrate diet. The overall diet effect varies with age, lifestyle,
intestinal microbiome, circadian rhythms (what time you eat), and lipid processing enzymes
(lipases, lipoxygenases), which modify progression or repression of various diseases such as
cardiovascular disease. Thus, dietary and nutrition research linking to obesity-related
outcome surprisingly leads to more questions and convolution than a precise answer
(Casazza et al., 2013). Until now, diet and obesity research has directed its focus on
energetics and micronutrients such as protein, carbohydrates, and high/low fat, but very few
groups have recognized that not all fats are created equal (Halade et al., 2012; Ramsden et
al., 2011; Spector and Kim, 2015). Moreover, the requirement of fat or metabolic energy
intake changes as the individual transitions throughout life and subsequently regulates
immune cell phenotype and milieu. In this review, we propose two emerging and essential
concepts of diet-enzyme interaction and diet-body interaction to form bioactive mediators.
This is exemplified with therapeutic application of potent specialized pro-resolving
biomolecules using the Fatty Acid Drug Discovery (FADD) approach. As the title indicates,
we address two major concepts in the present study; the first concept is the role of EPA and
DHA in health and second is metabolic transformation into a wide range of bioactive lipids,
including specialized pro-resolving mediators (SPMs). FADD-derived novel biomolecules
are proposed as a solution to resolve inflammation in differential acute and chronic disease
pathology, including myocardial infarction, rather than a micronutrient approach. From the
perspective of diet and nutrition, it is important to focus on dietokinetics or nutritkinetics,
(Motilva et al., 2015; van Velzen et al., 2009) which can be defined as the body’s ability
with the help of enzymes to absorb, distribute, store, metabolize, and excrete fat similar to
any other dietary substance. The key functional effect of diet/nutrients on the body is termed
“dietodynamics” or “nutridynamics,” which can be defined as the effect(s) of metabolized
biomolecules on the body in homeostatic conditions or in disease pathology. Some reports
on fat will measure outcome irrespective of nutritkinetics or dietokinetics. Dietodynamics or
nutridynamics can be studied in many interventions with specific emphasis on one
macronutrient. Now, with advances in mass spectrometry-based lipidomic and metabolomic
analytical technology, it is feasible to determine that specific fatty acids or lipid molecules
can be metabolized into a number of bioactive molecules in response to stress, exercise,
infection, or injury with the help of different metabolizing body enzymes (lipoxygenase
(LOX), cyclooxygenase (COX), and cytochrome p450 (CYP) epoxygenase). The availability
of lipid substrates and the activity of specific enzymes are prime factors to determining the
nutrikinetics or nutridynamics for individual homeostasis, disease progression, resolution,
and repression of disease pathology. Of note, these pathways are of significant importance
for pain, infection, immunity, inflammation, stress, and exercise to develop novel
pharmaceutical agents and have been since the beginning of drug discovery. Importantly,
many drugs like aspirin, ibuprofen, diclofenac, misoprostol, paracetamol, montelukast,
zafirlukast, pranlukast, zileuton, atorvastatin, simvastatin, lovastatin, cerivastatin, and
sulindac interfere with these complex metabolic pathways.
The metabolic transformation of omega-3 fatty acids (DHA and EPA) and omega-6 fatty
acids (arachidonic acid; AA) into various mediators is provided in Figure 2. To exemplify
the FADD approach, metabolic transformation of DHA and EPA into biomolecules is
displayed in Figures 3 and 4 respectively. DHA and EPA are transformed into various
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species of monohydroxy DHA/EPA, dihydroxy DHA/EPA, and trihydroxy DHA/EPA with
varying degrees of pro-resolving capacity. DHA- and EPA-derived lipid resolvin
biomolecules are metabolites of marine oil component with enormous potential to resolve
inflammation (Serhan, 2014). Therefore, DHA and EPA arguably contribute to preventing
cardiovascular disease and, more specifically, chronic heart failure (De Caterina, 2011). In
focusing on the effects of DHA, it could be postulated that the bioactive fatty acid may be a
pro-resolving agent in heart failure pathology. To accomplish this, reverse pharmacology can
be employed to other fatty acids as method that focuses on a translational, or bench-tobedside approach. This is based on traditional observation, advancement of precise structural
elucidation from the Serhan laboratory, and nutritional immunology knowledge that apply to
reversing the discovery trend from classical laboratory-to-clinic pathway to preventive,
precise, personalized, and prognostic therapy (Dalli and Serhan, 2017; Serhan et al., 2017).
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5. Essential fatty acids in health and disease

Author Manuscript
Author Manuscript

In 1929, Burr and Burr performed the first landmark survival study in rats without fatty acid
droplets in their diet. Data from this study suggest that dietary fatty acids are essential for
health and to prevent a series of diseases that were otherwise observed in rats fed a fat-free
diet (Burr and Burr, 1973; Smith and Mukhopadhyay, 2012; Spector and Kim, 2015). Burr et
al. coined the term “essential fatty acids” by identifying the fatty acids that cannot be
synthesized by the body and, therefore, are critical for optimal health. Burr and Burr
described the fat-free diet in great detail with the complete description of fat deficiency
disease. The results proved that dietary fat is required to stimulate growth and prevent
disease in humans and rodents (Burr and Burr, 1973; Hibbeln et al., 2006; Spector and Kim,
2015). The human body primarily depends on essential fatty acids in the diet, as well as the
intake of fatty acid precursors, which are endogenously elongated and desaturated into long
chain fatty acids. Accordingly, physiological and metabolic functions are mediated by the
availability of long-chain polyunsaturated fatty acids (PUFA: >20 carbon chain length) with
high levels of unsaturation (3–6 double bonds in structure). Later in 1970, Danish physicians
Jorn Dyerberg and colleagues observed that Greenland Eskimos consuming fish-enriched
nutrition had low incidences of heart disease (Bang et al., 1980). Fast forward to 1957, the
use of fish oil as a dietary supplement or a DHA- (22:6n-3) and EPA- (20:5n-3) enriched
diet was, and still is, recommended in order to prevent cardiovascular disease by many
societies, including the American Heart Association and the European Cardiovascular
Society (Dalen and Devries, 2014). As a result, the therapeutic drug Omacor (Reliant Inc.
USA), currently known as Lovaza® by GlaxoSmithKline in North America (St Petersberg,
FL, USA), was originally developed (Pronova Biocare, Lysaker, Norway) and approved for
post-infarct patients in Europe since 2001 (Calder, 2013). These concentrated omega-3-acid
ethyl esters (1000 mg to 4000 g/day) are approved for the treatment of hyperlipidemia, or
high levels of marine lipids in the blood (2014; Lavie et al., 2009). As of today, the
dietokinetics or nutrikinetics and dietodynamics or nutridynamics of these fatty acids in the
physiological and pathological setting that spans from birth to aging are unclear. In contrast,
fatty acids with one or more double bonds in trans-configuration, or trans-fatty acids, induce
cardiovascular events and systemic inflammation (Mozaffarian et al., 2004a; Mozaffarian et
al., 2004b). During this slow development in fatty acid knowledge and health benefits, Ancel
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Keys’ seven countries study results mislead with the conclusion that fat is the primary factor
for cardiovascular disease, without accounting nutrikinetics and nutridynamics in rodents or
humans (Keys, 1957; Keys et al., 1984). Traditionally, there are three major classes of
circulating lipoproteins based on lipid and protein composition: 1) very low-density
lipoproteins (VLDL), 2) low-density lipoproteins (LDL), and 3) high-density lipoproteins
(HDL). With the advancement of lipid-protein research, further sub-classes within these
classes of complexes and the various molecular components have emerged (2002). The lipidlowering therapy is focused on LDL-lowering agents to reduce atherosclerotic
cardiovascular disease risk (Lloyd-Jones et al., 2016). Of note, the overall presumed
hypothesis that trans fats are unsafe was originally developed by Kummerow (Kummerow,
1979). With the advancement of the LIPID MAPS initiative, the lipids have been further
reclassified into six major classes (Fahy et al., 2011; Fahy et al., 2005; Fahy et al., 2009;
Fahy et al., 2007). Lack of quantitative analytical technology would be the primary cause of
overall misunderstanding in fat convolution. Recent evidence suggests that single nucleotide
polymorphisms in the fatty acid desaturase 1 and 2 (FADS 1/2) gene cluster influence an
individual’s response to fat via either omega-3 or -6 fatty acids, affecting the subsequent
production of pro-inflammatory and pro-resolving molecules (Roke and Mutch, 2014).

Author Manuscript

In general, fatty acids represent 30–35% of an individual’s total energy intake and are
obtained from various sources, including plants, animals, and microbes, presented in Table 1
(Simopoulos, 2000). Fatty acids act as gene regulators and are essential components of the
cell and mitochondrial lipid bilayer membranes (Royce et al., 2013). An increase in cisunsaturated fatty acid percentage enhances membrane fluidity and also alters associated
physiological functions (Yang et al., 2011). The role of fatty acids is not only restricted to
governing membrane fluidity, but they also activate several native metabolic pathways useful
in fighting life-threatening disorders, such as α-secretase-dependent amyloid precursor
protein processing, which helps control Alzheimer’s disease (Sioen et al., 2006). Fatty acids
are delivered to the heart using fatty-acid-binding proteins (FABP). In fact, several
membrane-associated FABP have been reported, collectively also referred to as fatty acid
transporters for cellular entry of fatty acids (Glatz et al., 2010). The cytoplasmic FABPs
allow binding of fatty acids and uptake into cytoplasm via different organelles for various
functions, such as by lipid droplets for storage; by endoplasmic reticulum for signalling,
trafficking and membrane synthesis; by mitochondria or peroxisomes for oxidation; and by
the nucleus for the control of lipid-mediated transcriptional programs (Schaap et al., 1999).

Author Manuscript

Common fatty acids were classified on the basis of the number of carbon atoms and extent
of carbon-carbon saturation. Furthermore, the extent and number of double bonds in the
carbon backbone define a fatty acid as either saturated or unsaturated (Table 1). Based on
dietary requirements, fatty acids are classified into two major classes: essential and nonessential (Russo, 2009). Naturally occurring fatty acids are often derived from olive oil,
soybean oil, legumes/pulses, flaxseed, almonds, and a variety of nuts and seeds. In general,
the human body depends on the dietary source of the fatty acids that are required for normal
physiology and cannot synthesize several vital fatty acids, which must be obtained from the
diet. Two fatty acids are known to be an essential for humans: alpha-linolenic acid (an
omega-3 fatty acid) and linoleic acid (an omega-6 fatty acid) (Chang et al., 2009). Among
all the natural sources, vegetable oils are good sources of essential fats; however, the desired
Biotechnol Adv. Author manuscript; available in PMC 2019 July 01.
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ratio of omega-6 to omega-3 is important and should be ~ 5:1 (Kohli and Levy, 2009).
Excess intake of omega-6 in aging populations leads to obesity, bone loss, and many other
chronic inflammatory disease (Alvheim et al., 2014; Fernandes, 2008; Halade et al., 2011a;
Halade et al., 2010c; Lopategi et al., 2016; Patterson et al., 2012; Simopoulos, 2002, 2016).
Essential fatty acids are beneficial in attenuating a number of diverse pathological conditions
such as cardiovascular disease, chronic pulmonary airway disorders, neurodegeneration, and
cancer (Das and Fams, 2003; De Caterina, 2011). The optimum intake of fatty acids in the
diet improves cardiovascular functions, including anti-inflammatory properties, reduced
major coronary events and improved anti-platelet effect (Akbar et al., 2005; Mori et al.,
2003; Wanga et al., 2014). With urbanization, the levels of omega-6 fatty acids, such as AA
and LA, have increased in the American diet, but the levels of conditional fatty acids such as
EPA and DHA remain unchanged or even reduced. Of note, DHA and EPA act as precursors
for several bioactive metabolites (eicosanoids/lipid mediators) that are beneficial in the
prevention or treatment of several diseases (Figure 2) (Wolk et al., 2006). With recent
advancement in lipidomics and metabolomics mass spectrometry technology, it is feasible to
determine the nanogram and picogram levels of DHA and EPA-derived lipid metabolites.
Furthermore, a series of studies in-vitro and in-vivo has explored the potential of these
molecules to resolve inflammation, which is completely different than inhibition of
inflammation (Bannenberg, 2009). It has been reported that DHA and EPA are centrally
associated with the pathophysiology of atherosclerosis and chronic inflammation
(Simopoulos, 1991).
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Clinical interventions and trials established that EPA and DHA lower cardiovascular risk in
patients with type 2 diabetes without adversely affecting glycemic control (Bradberry and
Hilleman, 2013). Recent studies have demonstrated that Lovaza®, an omega-3 fatty acid
ethyl ester, is effective in coronary heart disease by regulation of severe
hypertriglyceridemia. Lovaza® is commercially available in capsule dosage form by GlaxoSmith-Kline to treat hyperlipidemia. Clinical studies carried out since 2000 have revealed
the potential of omega-3 fatty acids to protect against cardiac disorders and their derivatives,
including EPA, DHA, ALA, and IPE (icosapent ethyl; contains high-purity EPA ethyl ester).
During clinical trials, omega-3 fatty acids with brand names, such as GISSI–Prevenzione,
JELIS, ORIGIN, and Su.Fol.Om3, etc., were studied in different patients groups. Each
clinical trial was attributed to a specific group of patients with its pros and cons, but the
omega-3 fatty acids were overall effective in controlling cardiac disorders (Herrera et al.,
2015).
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At the same time, the negative report of the omega-3 products cannot be ignored. In spite of
their benefits, omega-3 fatty acids were reported ineffective in reducing cardiovascular risk
when consumed at a lower dose or in combination with different fatty acids (Eckel, 2010).
Surprisingly, a clinical study demonstrated omega-3 fatty acid supplementation failed to
provide a protective role in statistically lowering the risk of mortality in the cardiac death,
sudden death, myocardial infarction, or stroke (Rizos et al., 2012). Meta-analysis studies
suggest the use of omega-3 PUFAs and reconsideration of supplement dose, adherence,
baseline intake, and CVD risk. Despite these negative aspects, EPA and DHA both are
associated with the prevention and management of cardiovascular disease, hyperlipidemia,
hyperinsulinemia, and possibly type 2 diabetes (T2D) by lowering triacylglycerol
Biotechnol Adv. Author manuscript; available in PMC 2019 July 01.
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concentrations (Merched et al., 2008). Interestingly, EPA and DHA were reported beneficial
in coronary heart disease, not only by altering serum lipids, but also by reducing blood and
ventricular arrhythmias (Abedi and Sahari, 2014; Kain and Halade, 2017; Tomio et al., 2013;
Uderhardt et al., 2012; von Schacky, 2007).

6. Not all fats are created equal - elongation, diversified, and contrasting
effects
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FADS are the best categorized genes shown to influence circulating and membrane PUFAs.
FADS encode fatty acid desaturase enzymes that regulate the endogenous metabolism of cis
omega-3 and omega-6 fatty acids, termed FADS1 and FADS2, respectively. These
biologically-relevant candidate genes encode the delta-5 and delta-6 desaturases, which
participate in the metabolic conversion of the essential fatty acid linoleic acid (LA) to longer
chain omega-6 fatty acids. Stoffel and his colleagues confirmed that fatty acids are not only
essential constituents for membrane phospholipids, but are also precursors for eicosanoids,
anandamides, and docosanoids. The deficiency of essential fatty acids and eicosanoids
allows a normal lifespan for male and female FADS2 (synonym- delta-6 fatty acid
desaturase; D6D) null mice, but impairs reproductive abilities (Stoffel et al., 2008).
Furthermore, Stoffel extended his findings and developed auxotrophic FADS2 mutant mice
(omega-6-fatty acid desaturase) that are resistant to obesity. The essential fatty-acid-deprived
FADS2 null mice were obesity-resistant and enriched with eicosa-5,11,14-trienoic acid.
Altered lipid metabolism in FADS2 null mice suggested that membrane-bound phospholipid
species are critical for the structural and operative functions in lipid homeostasis in normal
physiology, as well as pathophysiology (Stoffel et al., 2014). With the observed specific and
divergent effects of different fatty acids, it is the consensus in the scientific and medical
communities that individuals should be prescribed more omega-3 and fewer omega-6 PUFAs
in order to achieve optimum cardiovascular benefits (Harris and Shearer, 2014; Patterson et
al., 2012). However, an excess of omega-6 fatty acid remains elevated in the Western diet.
The availability of linoleic acid in the diet increased in the 20th century from 2.79% to
7.21%, with limited change in α-linolenic acid intake, which increased from 0.39% to
0.72% from dietary energy source. Fatty acids alter the physiology and pathology of target
organs, providing that the metabolism of fatty acids depends on the activity of enzymes,
such as stearoyl-CoA desaturase (SCD), delta-5 (D5D) and delta-6-desaturase (D6D).
Three-weeks-long, controlled diet studies of saturated fats and PUFA in humans suggested
that saturated fat intake stimulated SCD and D6D activity, while D5D activity was lowered.
This all occurred without impacting levels of DHA or EPA. In fact, docosapentaenoic acid
(DPA) levels were significantly higher after a saturated fat diet intake, suggesting an
increase in D6D activity. Moreover, humans who were provided with saturated fats and
PUFA had the same concentration of AA, mainly derived from LA, which contributes to the
formation of eicosanoids (Warensjo et al., 2008). Evidence confirms that palmitic acid, but
not stearic acid, leads to increased mortality, particularly as a result of cardiovascular
disease. Intake of PUFA (LA) reduced the severity of cardiovascular disease, which was
independent of desaturase activity (Warensjo et al., 2008).
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Metabolic changes in fatty acid products in the heart are also controlled by D6D activity.
Hyperactivity of D6D leads to the conversion of LA into AA, and the presence of the AA
metabolites is reflected in dilated cardiomyopathy. In heart failure, there are higher levels of
AA in membrane phospholipids due to higher activity of D6D, but utilization of these fatty
acids remains unclear. Fatty acids are either used for energy or for formation of eicosanoids
or docosanoids. Inhibition of D6D (SC-26196) reversed phospholipid remodeling and
reduced the levels of AA and DHA in heart failure rat models and also reduced levels of 5hydroxy eicosatetraenoic acid (HETE), 12-HETE, 15-HETE, and TXA2. As a result of the
inhibition of D6D, there is altered phospholipid membrane remodeling in the heart and
improved ventricular function with reduced fibrotic hypertrophy (Le et al., 2014). Thus, the
overall intake of omega-6 increased, but the intake of omega-3 fatty acids, such as DHA,
EPA, and DPA, had been continuously lowered, suggesting the predisposition of human
health to many pro-inflammatory conditions (Blasbalg et al., 2011). American dietary
guidelines recommend 1 gram of EPA+DHA per day to be given to coronary heart disease
patients and 3–4 grams of EPA+DHA per day to patients with high triglyceride levels. Very
high doses of fish oil products (about 3–12 grams) can lower triglycerides by 20–50%,
though they have no benefit in preventing pancreatitis, which is a major risk in patients with
high triglycerides (2014). The use of fish oil to lower the risk of mortality, cardiac death,
sudden death, myocardial infarction, and stroke are based on relative and absolute measures
of cardiovascular health and include associations that cannot be ignored (Rizos et al., 2012).
These diversified, paradoxical, and multidimensional findings provide rationale to develop a
theory about DHA and EPA lipid metabolites that can be extrapolated to DPA and other fatty
acids in order to provide strong rational and pharmacological evidence in disease pathology.
In fact, recent evidence indicates that novel omega-3 DPA oxygenated products (RvTs) are
catalyzed by COX-2 and exert potent anti-inflammatory and tissue-protective actions in an
in vivo murine hind limb ischemia reperfusion model of second organ injury (Dalli et al.,
2013).

7. Omega-3 and omega-6 fatty acids imbalance in disease pathology

Author Manuscript

Ramsden et al. performed a randomized, single-blinded trial and established that high
omega-3 fatty acids combined with low omega-6 fatty acids promotes more anti-nociceptive,
or pain-relieving mediators than low omega-6 fatty acids alone (Ramsden et al., 2013). This
trial provides evidence that a combination of dietary omega-3 fatty acids with a concurrent
reduction of omega-6 fatty acids reduces chronic daily headache pain. This specific trial was
conceptualized with the aim to observe anti-nociceptive outcomes, either due to low
omega-6 fatty acids or high omega-3 fatty acids plus low omega-6 fatty acids. However, the
outcome was negative only in low omega-6 fatty acids group, which suggests that an
optimum balance is required in order to reduce chromic pain. Reduced pain in a clinical
setting in a low omega-6 fatty acid plus high omega-3 fatty acids group was supported by a
marked increase of anti-nociceptive omega-3 derivatives 18-HEPE and 17-HDHA
(precursors to E- and D-series resolvins) (Ramon et al., 2012; Ramsden et al., 2013;
Tjonahen et al., 2006). Omega-6 AA, which was significantly reduced in erythrocytes by the
high omega-3 and low omega-6 fatty acids, but not in the omega-6 fatty acids intervention, is
the biosynthetic precursor to a variety of pro-nociceptive and vasoactive lipid mediators
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implicated in headache pathogenesis (Ramsden et al., 2013). Furthermore, high omega-3
fatty acid plus low omega-6 fatty acid intervention significantly reduces numerous hydroxy
octadecadienoic acid (HODE) and HETE derivatives of omega-3 LA and omega-6 AA,
compared to baseline. The majority of HODEs and HETEs have putative pro-nociceptive
properties by acting as endogenous ligands for the vanilloid (TRPV1) receptor channel (i.e.,
endovanilloids) (Hwang et al., 2000; Patwardhan et al., 2010; Ramsden et al., 2013). No
beneficial outcome of pain reduction was observed in a controlled trial to test the efficacy of
a diet of only omega-3 fatty acids (DHA+EPA) (Pradalier et al., 2001). Conversely, an
intervention using a low dose of EPA+DHA yielded comparative results to high omega-3
fatty acids plus low omega-6 fatty acids intervention. The outcome from this study
exemplifies that a dietary omega-6-lowering component is essential in order to reduce
chronic pain, as well as to observe the maximum benefit of omega-3 fatty acids in disease
pathology (Ramsden et al., 2013). Recent investigations have suggested that lower plasma
levels of omega-3 fatty acids leads to an increased risk of cardiac death. Moreover, the
beneficial versus harmful effect of omega-6 fatty acids debate is still ongoing (Calder and
Deckelbaum, 2011). It has been proposed that omega-3 index is a new risk factor for death
from coronary artery disease, especially following sudden cardiac arrest from a study using
human samples (Schacky, 2010). It is important to note that catalyzing enzymes define the
fate of omega-3 LA, EPA, and DHA.

8. Fatty acid processing enzymes: lipoxygenase (LOX), cyclooxygenase
(COX), and cytochrome P450 (CYP) epoxygenase
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In physiological and pathological stress, fatty acids undergo a series of enzymatic or nonenzymatic breakdowns to produce potent bioactive lipid mediators with diverse
pharmacological activity (Funk, 2006; Levy, 2010). Three major pathways associated in
fatty acid metabolism are LOX, COX, and CYP. The COX, LOX and CYP pathways result
in production of mediators that initiate, resolve, or progress inflammation depending on the
type of activity and fatty acid substrate (Halade et al., 2016; Halade et al., 2017; Khanapure
et al., 2007; Kim et al., 2008). It has been established that eicosanoids play an important role
in the initiation, progression, and resolution of inflammation (Uderhardt et al., 2012).
Leukocyte-type 12/15-lipoxygenase (12/15-LOX) has been identified as a major enzyme in
the production of anti-inflammatory lipid mediators (lipoxins) (Uderhardt and Kronke,
2012). However, 5-LOX is involved in the generation of leukotrienes (LTs), which initiate
inflammation via production of 5(S)-hydroperoxy-6-trans-8,11,14-cis-eicosatetraenoic acid
(5-HpETE) (Radmark and Samuelsson, 2009). Further, HpETE acts as precursor for the
lipoxins including LXA4 and LXB4. In fact, in 2009 Gerhard Kronke et al. demonstrated
that deletion of the leukocyte-type 12/15-LOX gene leads to uncontrolled inflammation and
tissue damage (Kronke et al., 2009).
Studies have shown enhanced inflammatory gene expression and decreased levels of LXA4
in 12/15-LOX-deficient mice. These findings were further supported by the antiinflammatory and tissue-protective role of 12/15-LOX reported by Olof Radmark et al.
(Radmark and Samuelsson, 2009). Future experiments with major emphasis on a substrateand organ-specific role of 12/15 LOX is essential for tissue and organ regeneration and
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restoration of function. In this context, cardiac tissue could be an ideal target to explore
12/15-LOXs’ activity and robustness towards the biosynthesis of pro-resolving lipid
mediators. Fatty acid metabolism varies among different tissues, mostly adipose tissue,
skeletal muscle, and liver, which possess complex mechanisms. For an enzyme, the activity
remains a function of its structural configuration and kinetic constants, hence profiling this
enzyme at proteomic and biophysical levels will lead to the understanding of molecular
insights specific to particular tissues/organs. Similarily, the distribution of fatty acids in
different tissues and organs is not homogeneous. Therefore, the enzyme activity (12/15
LOXs) and biosynthesis of pro-resolving lipid mediators in the course of inflammation
resolution also varies depending on type and availability of fatty acid substrate. To
understand and explore pro-resolving lipid mediator(s) biosynthesis in varying substrates
(quantitative and qualitative), immediate attention is required to explore the efficacy of
12/15-LOXs in diverse disease pathologies.
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LOXs are complex enzymes, involved in oxidative and redox metabolism of PUFAs. They
also possess an affinity for different substrates, which results in various oxylipid mediators
(Radmark et al., 2007). The enzyme 15-LOX catalyzes the production of 15 (S)-HpETE as a
key intermediate from AA and acts as a precursor for lipoxin, which possesses excellent
anti-inflammatory activity. Additionally, 15-LOX also catalyzes the production of 17-(S)HDHA from docosahexaenoic acid (DHA), which is further metabolized to produce
resolvins (D-series) (Xu et al., 2006). The outcome of such unique catalysis results in the
production of specialized pro-resolving mediators (SPM), including protectins and maresins.
An enzyme’s ability to catalyze multiple biochemical reactions is known as enzyme
promiscuity or, more precisely, catalytic promiscuity (Khersonsky and Tawfik, 2010).
Furthermore, resolvins and 5-LOXs are involved in the catalysis of 5(S)-Hp-ETE, 15(S)HpETE, 17-(S)-HpDHA, 15(S)-HpEPA that results in protectins, which actively participate
in the resolution of inflammation (Bannenberg and Serhan, 2010; Hao and Breyer, 2007).
12-LOX exists as two isoforms, platelet-type and leukocyte-type, which catalyzes the
formation of 12-HpETE from AA. Both isoforms of 12-LOX share 60% identity at the
amino acid level and strongly differ in substrate specificity and enzyme kinetics (McDonnell
et al., 2001; McDonnell et al., 2002). One possible reason for enzyme promiscuity in the
LOX enzyme is due to the unique catalytic site, which rapidly transitions to develop an
affinity for various substrates. The concept of enzyme promiscuity in the LOX enzyme is
operational in time-dependent manner in inflammation and disease pathology. A detailed
understanding of LOX catalytic promiscuity will result in a novel approach in drug
development process (Verma and Pulicherla, 2016). LOXs are the key enzymes in oxidative
breakdown of these lipids, resulting in bioactive lipid mediators and offering a broad
spectrum of physiological function (Massey and Nicolaou, 2013). A detailed scheme of
metabolites produced by a series of enzymatic activity is shown in Figure 2. Furthermore,
CYP epoxygenase is reported as a key enzyme in the biosynthesis of bioactive lipid
mediators with significant biological importance (Fischer R, 2014; Lands, 2012). CYP
epoxyegnase has shown potent cardiovascular protective action and potential for coronary
artery disease drug development. A preclinical study in patients referred for coronary
angiography demonstrated lower EET metabolite levels, secondary to suppressed EET
biosynthesis (Oni-Orisan et al., 2016). However, lipid biochemistry has not been explored
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completely, as several mediators, such as 20-HEPE and 20-HDPE, are derived from EPA and
DHA respectively under activity of CYP hydroxylase (Johnson et al., 2015). Along with
LOXs, COXs (COX-1 and COX-2) are membrane-associated homodimer hemoproteins
actively involved in oxygenation of lipids, which results in an array of bioactive lipid
mediators with diverse pharmacological activities (Picot et al., 1994). Naturally occurring
COXs exist in two isoforms and possess peroxidase and oxygenase active sites on the same
molecule (Smith et al., 2000). The function of COX is largely dependent on cofactor
attachment (heme), which is responsible for substrate activation of the active site by
oxidizing tyrosine residues (Tyr385). In a sequential manner using the same active site,
COXs are involved in two oxygenation reactions (first in 11R configuration and second in
15S configuration) using AA as a substrate, resulting in prostaglandin endoperoxides
(Rouzer and Marnett, 2003). Thus, similar to LOXs, COXs are dioxygenases and two
isoforms, COX-1 and COX-2, catalyze similar reactions for prostanoid biosynthesis. AA
remains the prime substrate for COXs, while other fatty acids have an affinity for COXs in
different capacities. It has also been reported that selective COX-2 inhibitors are key drug
molecules resulting in a higher percentage of myocardial infarction and stroke events. The
selective COX-2 inhibitors are associated with inhibition of prostacyclin (PGI2), lipoxins,
resolvins, and endothelial nitric oxide (e-NO) biosynthesis (Das, 2005). Metabolism and
dietary intake of essential fatty acids via COXs and LOXs drive pathways to reduce the
percentage of global disease burden including coronary heart disease, stroke, diabetes
mellitus, hypertension, cancer, depression, schizophrenia, Alzheimer’s disease, and vascular
diseases (Das, 2008; Kain and Halade, 2017).

9. DHA metabolites in pro-resolution therapy
Author Manuscript
Author Manuscript

Omega-3 fatty acids play an important role in preventing the negative effects that are
associated with chronic inflammation. Omega-3 substrates such as EPA, DHA, and DPA, are
metabolized into intermediate lipid mediators including monohydroxy, dihydroxy, and
trihydroxy molecules. Many of the dihydroxy and trihydroxy molecules, which carry
potential bioactivity, are referred to as resolution phase interaction products (resolvins; D
series and E-series depending on DHA or EPA metabolite). Direct cell-cell interaction of
leukocytes and platelets organizes synthesis of DHA-, EPA-, and DPA-derived biomolecules,
which limit the activity of pro-inflammatory leukocytes, while also increasing the activity of
pro-resolving inflammatory mediators (Serhan, 2014). To exemplify the promise for FADD,
this section of the review focuses exclusively on the DHA and EPA bioactives, commonly
known as SPMs. DHA metabolites are commonly referred to as D-series resolvins 1-6 (RvD
1-6), protectins, and maresins. Our study identified that DHA is more effective in extending
the lifespan of lupus-prone inflamed mice (Halade et al., 2010a) and attenuates breast cancer
bone metastasis (Haworth et al., 2008). Similarly, EPA transforms to E-series Resolvins
(RvE1-3) and AA to lipoxins, prostaglandins, and leukotrienes (Serhan, 2014).
9.1 Monohydroxy DHA
Wound healing is the first step in the response mechanism to cutaneous or sterile injury, such
as myocardial infarction or stroke, which is characterized by immune cell trafficking. At the
local tissue level, healing is a programmed event that is coordinated by the generation of
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SPMs, which are produced by the interaction of platelets, neutrophils, and macrophages at
the site of injury or in the spleen reservoir. The generation of specialized resolving mediators
in the acute inflammatory phase, overlapping with resolving response programs, may lead to
the termination of injury-mediated inflammation. In genetically diabetic mice (db/db),
apoptotic neutrophil clearance is delayed and DHA metabolites levels are lowered, despite
having bioequivalent levels of DHA molecules in the cutaneous wound healing model.
Reduced levels of monohydroxy DHA metabolites (4-HDHA, 14-HDHA and 17-HDHA)
significantly impair cutaneous wound healing and continue non-resolving inflammation,
suggesting the presence of chronic inflammation (Tourki and Halade, 2017). Monohydroxy
DHA serves as the precursor for these resolving molecules, such as maresins, protectins, and
resolvins. It has been shown that Resolvin D1 (RvD1) administration improved healing of
diabetic wounds, as RvD1 stimulates macrophage phagocytosis and emigration from healing
site. Topical application of RvD1 suppressed diabetes-mediated defective wound healing in
mice (Tang et al., 2013). Thus, it can be determined that the diabetes-mediated defective
systemic wound healing inflammatory response is ameliorated by RvD1 to promote a
compensatory resolving response.

Author Manuscript

Omega-3 fatty acids produce molecules called hydroxy-docosahexaenoic acids (HDHA)
using LOX. A study performed by Sapieha and colleagues showed that the presence of 4HDHA in the human blood increases 20-fold compared to that of 7-HDHA when associated
with blood clotting (Sapieha et al., 2011). The high concentration of 4-HDHA compared to
that of 7-HDHA was also observed in isolated mouse neutrophils in a study that aimed to
determine the activity of 5-LOX in the presence of calcium ionophore with exogenous DHA.
This report showed that the presence of 5-LOX-derived 4-HDHA and the PPARγ receptor
have a role in the anti-angiogenesis that is associated with omega-3 PUFAs (Sapieha et al.,
2011). A study performed by Ramon et al. found that another molecule, DHA-derived 17HDHA, can aid the adaptive immune response initiated by vaccines. Administration of 17HDHA in conjunction with an influenza vaccine increases antibody production in a mouse
model. This response elicited better protection against a pandemic H1N1 infection compared
to that of the wild-type (Ramon et al., 2014). DHA-derived 17-HDHA has a direct role in
the differentiation of B cells, initiating antibody secretion. Ramon and colleagues reported
100% survival rate of the mice that were injected with the vaccine and 17-HDHA, as
compared to a previous study that showed 80% survival in mice only treated with the
vaccine, indicating the potency of this lipid-derived pro-resolving mediator (Ramon et al.,
2012).
9.2 Resolvin D1
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RvD1 (7S,8R,17S-trihydroxy-4Z,9E,11E,13Z,15E,19Z-docosahexaenoic acid) is one of a
series of six common pro-resolving molecules (RvD1-6) that are derived from DHA. RvD1
pharmacological potency has been tested in-vitro and in a number of in-vivo disease
pathology models (Table 2) (Cianci et al., 2016; Croasdell et al., 2015; Gilbert et al., 2015a;
Hodges et al., 2016; Kain et al., 2015; Norling et al., 2012; Titos et al., 2011). In the surgeryinduced myocardial infarction model, during which the left anterior descending coronary
artery is permanently ligated, it was observed that RvD1 accelerated neutrophil clearance
and increased macrophage clearance from the injured left ventricle, preventing immune cell
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accumulation at the sit of injury (Kain et al., 2015). In response to the occlusion of the left
coronary artery caused by this sterile ligation procedure in mice, there is rapid trafficking of
neutrophils, monocytes, and macrophages, which leads to fibrotic scarring on left ventricle
(Kain et al., 2014; Lopez et al., 2015; Ma et al., 2013). Post-MI myocardium injury recruits
immune cells from the spleen reservoir and stimulates repair of damaged myocardium.
Metabolomic profiling of the spleen indicates that the spleen triggers the production of lipid
mediators, including RvD1, Maresin 1 and Lipoxin A4, which promote self-resolution of
inflammation at the left ventricular site. Subcutaneous administration of RvD1 increases the
clearance of neutrophils from the spleen and promotes macrophage clearance from the
healing site. RvD1 acts primarily on the ALX/FPR2 receptor in spleen and left ventricle to
promote effective resolution of inflammation. It is of importance to note that the mRNA
expression of ALX/FPR2 receptor is >50% higher in the spleen than the LV. This indicates
the presence of a cardiosplenic axis, which suggests that the spleen plays a pivotal role in
post-MI cardiac healing and remodeling. Thus, the overall effective coordination of
neutrophil and macrophage kinetics by SPM in the spleen and left ventricle promotes
healing and can, therefore, delay heart failure. A reperfusion study confirmed that
intraventricular administration of RvD1 reduces myocardium infarct size; however, presence
of linoleic acid attenuates the cardioprotection offered by RvD1 (Gilbert et al., 2015b)
(Gilbert et al., 2016).
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A study performed by Norling et al. showed that RvD1 reduced polymorphonuclear (PMN)
leukocytes in an acute peritonitis human cell model. The key mechanism is largely
controlled by RvD1 interacting with PMN cell receptors, FPR2/ALX and GPR32. In vivo,
Norling used a peritonitis murine model to show that there is a decrease in pro-inflammatory
leukocyte recruitment in wild-type mice when treated with RvD1. This was not seen in the
fpr2-null mice (Norling et al., 2012). This indicates the importance of direct interaction of
RvD1 with the FPR2 receptor for anti-inflammatory actions. In a study of RvD1 action in an
obesity mouse model, the metabolite was shown to cause the responding macrophages to
express an M2-like phenotype, which confers anti-inflammatory characteristics. This
reduces the activity of inflammatory cytokines, such as TNF-α and IL-6, which both
contribute to inflammation and, consequently, heart failure post-MI (Titos et al., 2011).
Receptors for RvD1 have been identified and described; the human GPR32 receptor has no
other identified ligands other than RvD1, whereas the ALX receptor is shared by both RvD1
and lipoxin A4 (Cheng et al., 2016). In the permanent coronary ligation mice model that
induces-myocardial infarction, Kain et al. demonstrated an improvement in fractional
shortening and reduction of the occurrence of fibrosis post-cardiac injury when treated with
DHA-derived RvD1 metabolite, which exemplifies its therapeutic utility in heart failure
(Kain et al., 2015) (Figure 5 showing multiple activities of RvD1 in resolution of
inflammation) (Hua et al., 2014; Kain et al., 2014; Kang and Lee, 2016; Norling et al., 2016;
Serhan, 2014; Shinohara et al., 2014). As expected, in a myocardial ischemia-reperfusion
model of injury, RvD1 reduces infarct size by modulating phosphoinositide 3-kinase/protein
kinase B (PI3K/Akt) pathway (Gilbert et al., 2015a). PI3K is the important signal
transduction enzyme responsible for the RISK signaling pathway. The PI3K/Akt pathway
itself limits pro-inflammatory response (Rice et al., 2016) and promotes myocyte survival
(Fujio et al., 2000), which leads to cardio-protection. Gilbert et al. showed that RvD1 has
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cardio-protective features, as treatment with higher doses (0.3 μg) of RvD1 was shown to
increase the expression the PI3K/Akt pathway (Gilbert et al., 2015a). RvD1 has also been
shown to be associated with decreased inflammation and oxidative stress in a cigaretteinduced emphysema mouse model. This study concluded that the administration of the proresolving mediator, RvD1, aids in the attenuation of chronic lung disease (Li et al., 2016).
9.3 Resolvin D2
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The next DHA-derived SPM is RvD2 (7S,16R,17S-trihydroxy-4Z,8E,10Z,12E,14E,19Zdocosahexaenoic acid), as it has been shown to play an anti-inflammatory role in different
infection and injury models (Chiang et al., 2015; Duffield et al., 2006; Spite et al., 2009;
Tian et al., 2015). According to Tian et al., RvD2 impedes lipopolysaccharide-induced
inflammation by the down-regulation of IL-6, NO, TNF-α, and IL-1-β in a rat model of
Parkinson’s disease (Tian et al., 2015). Similarly, it was shown that RvD2 prevents the
activity of reactive oxygen species, which are known to cause tissue injury during the
inflammatory response. In a murine model of ischemic acute kidney injury, it was shown
that levels of resolvins RvD2, RvD3 and RvD4 are increased in plasma during the
inflammatory phase. In this study, the mice also received exogenous DHA. RvD2, which
was not observed endogenously in renal tissue, increased in both the plasma and renal tissue
(Duffield et al., 2006). In the presence of RvD2 and bacterial infection in mice, the activity
of macrophages was increased, while there was a decrease in the response of cytokines
(IL-1β, IL-6, IL-23, and TNF-α) and neutrophils (Spite et al., 2009). This is especially
important, as the role of macrophages in the resolution of inflammation is essential for
clearing cell debris. It is unclear whether resolvins digest the necrotic cell organelle or
activate signals to remove the organelle from the injured or infected area. Chiang et al.
identified the RvD2 ligand primarily present in peripheral blood PMNs, monocytes, and
macrophages and its ability to induce its pro-resolving role using the GPR18 receptor
(Chiang et al., 2015). In this study, wild-type mice and GPR18 knockout mice were both
given exogenous RvD2 in the presence of a bacterial infection. The gpr18-null mice showed
non-resolving infection due to higher levels of PMN infiltration, a deficiency in the
phagocytosis of dying/dead cells (efferocytosis), and lower activity of macrophagecontrolled phagocytosis. Treatment of the wild-type mice with RvD2 had the opposite effect,
suggesting that there is a positive, pro-resolving reaction that occurs with the binding of
RvD2 to GPR18 (Chiang et al., 2015).
9.4 Resolvin D3
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RvD3 (4S,10,17S-trihydroxy-5E,7E,9E,13Z,15E,19Z-docosahexaenoic acid) and has been
argued to be one of the most potent of the D-series resolvins. RvD3 reduces the infiltration
and trans-endothelial migration of neutrophils in acute inflammation. Similar to RvD1, this
resolvin stimulates the proliferation of IL-10, which is a potent inhibitory factor of cytokine
synthesis (Lefkowitz, 2016). RvD3 mediated actions reduce the occurrence of collateral
tissue damage that is associated with prolonged inflammatory response. RvD3 also has been
observed to stimulate the phagocytosis of apoptotic neutrophils via macrophages, referred to
as efferocytosis (Nair et al., 2016; Oh and Lagakos, 2011). Though these characteristics are
similar to those of RvD1 and RvD2, RvD3 has been shown to persist throughout the
resolution timeframe post-injury, while RvD1 and RvD2 are present only in early resolution
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(Oh and Lagakos, 2011). The persistence of this pro-resolving molecule in the resolution
phase of injury recovery could be key to overall success and development of a solution to
inflammatory disease. RvD3 is of special interest because it controls the dysregulated
inflammation in aging populations. In a study performed by Arnardottir and colleagues
reported the resolution of inflammation in aging mice that were studied administered RvD1
and RvD3. Increased levels of RvD1 and RvD3 treatment stimulated increased monocyteaccelerated resolution of acute inflammation via efferocytosis (Arnardottir et al., 2014).
9.5 Resolvin D4
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RvD4 (4S,5,17S-trihydroxy-6E,8E,10E,13E,15Z,19Z-docosahexaenoic acid) is less
characterized than some of the other resolvins. However, RvD4 has been shown to act in a
similar way to the other DHA resolvin metabolites in that it reduces the activity of
neutrophils at the site of injury and increases the activity of macrophages in the clearance of
apoptotic bodies (Raetz et al., 2009). It is important to explore the abundance of proresolving lipid mediators, lack of DHA substrate or deficiency of DHA processing LOX
enzymes and their impact on resolving post-injury inflammatory response, compared to a
younger model. During S. aureus infection, RvD4 reduces neutrophilic infiltration and, with
time, enhances the uptake of apoptotic neutrophils by human dermal fibroblasts at
concentrations as low as 0.1 nM. RvD4 shows pro-resolution properties, remaining at
bioactive levels (~ pM) in the late stages of resolution (Velazquez and Grodecki-Pena,
2016).
9.6 Resolvin D5
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Resolvin D5 (7S,17S-dihydroxy-5Z,8E,10Z,13Z,15E,19Z-docosahexaenoic acid) regulates
the uptake of Escherichia coli (E. coli) by phagocytes in mice while also downregulating the
expression of NF-κβ and TNF-α. In conjunction with appropriate antibiotics, RvD5, along
with RvD1 and protectin D1, host antimicrobial response is increased, allowing for a higher
survival rate of an otherwise lethal bacterial infection (Chiang et al., 2012). The
downregulation of NF-κβ and TNF-α by RvD5 could be beneficial in the heart failure
model, as both of these factors are increased in the heart post-cardiac injury. A recent aging
metabolome study described that RvD6 levels (4S,17S-dihydroxy-5E,7Z,10Z,13Z,15E,19Zdocosahexaenoic acid), were decreased in aging process indicating the role of lipid
metabolism in progressive aging (Jove et al., 2016).
9.7 Resolvin D6
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Much like RvD4, RvD6 (4S, 17S-dihydroxy-5E,7Z,10Z,13Z,15E,19Z-docosahexaenoic
acid) is not as extensively characterized as other resolvins. A human aging metabolome
study suggests that RvD6 levels are decreased with increasing age (Jove et al., 2016). This
could be an indicator that the reduction in abundance of pro-resolving lipid mediators has a
possible significant impact on the aging and healing process. RvD6 is thought to also have
qualities that support the resolution of inflammation post-injury (Pietilainen et al., 2007).
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Similar to RvD1-6, protectin D1 (PD1) (10R,17S,dihydroxy-4Z,7Z,11E,13E,15Z,19Xdocosahexaenoic acid) is a metabolite of DHA that also exhibits pro-resolving properties.
PD1 was originally described as neuroprotectin D1 due to its anti-inflammatory effects in
the brain ischemia mouse model (Bazan, 2007). PD1 shares many of these characteristics
with the other D-series resolvins, as it lowers the activity of PMNs, down-regulates the
activation of pro-inflammatory molecules (NFκβ and COX-2), and increases macrophage
phagocytosis of apoptotic cells. PD1 also is engaged in damage control in the inflammatory
model, as it reduces the occurrence of apoptosis induced by oxidative stress (Schwab et al.,
2007). PD1 has been described to confer cell survival in a human ARPE-19 (retinal pigment
epithelia) cell model. It inhibited the activation of COX-2 and NF-κβ, which are genes that
have pro-inflammatory characteristics. By these means, the infarct area in brain ischemia is
reduced, conferring better survival (Bazan, 2006).
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9.9 Maresins
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In the carotid artery ligation mouse model, Akagi et al. hypothesized that treatment with
RvD2 or another pro-resolving D-series lipid mediator, Maresin 1 (MaR1) (7R,14Sdihydroxy-4Z,8E,10E,12Z,16Z,19Z-docosahexaenoic acid), prevented neointimal
hyperplasia, or the thickening of arterial walls post-injury (Akagi et al., 2015). Both RvD2
and MaR1 treatments decreased the amount of superoxide that the cytokine TNF-α
produced. The density and trafficking of neutrophils to the site of injury was reduced with
both treatments, though infiltration was reduced by 56% by MaR1 and only 48% by RvD2.
Phagocytic macrophage activity was reduced by 48% and 43% in this model by treatment
with RvD2 and MaR1, respectively. Thus, RvD1 and MaR1 showed potency to reduce
neointimal hyperplasia and contribute to translational use in disease pathology (Akagi et al.,
2015). These pro-resolving lipid mediators have been shown to confer healing in tissue postinjury. MaR1 has been shown to play a potent anti-inflammatory role in the resolution of
chronic inflammation in asthma. In a mouse model of allergic inflammation, Krisnamoorthy
and colleagues showed that MaR1 limits the activity of ILC2, which are innate lymphoid
cells that are significant in the propagation of allergic inflammation. Exogenous treatment of
inflammation with MaR1 increased the activity of regulatory T cells, which inhibit the
activity of ILC2 in mice (Krishnamoorthy et al., 2015). Furthermore, MaR1 treatment has
been shown to initiate the resolution phase in allergic inflammation of the lungs to occur
faster and more readily, decreasing the number of eosinophils in the bronchoalveolar lung
fluid. Cytokines such as IL-5 and IL-13 were decreased in the resolution phase as well, due
to the decreased activity of ILC2. Accordingly, the amount of active TGF-β, which alters the
profile of CD4+ T cells, and regulatory T cells were also increased (Krishnamoorthy et al.,
2015). Like other monhydroxy and dihydroxy DHA metabolites, MaR1 also exhibits
characteristics that cause pro-resolving effects due to its ability to block PMN-sustained
infiltration to the site of inflammation, while causing an increase in macrophage
phagocytosis (Serhan et al., 2009).
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10. EPA-derived bioactives with potential pro-resolving activity
10.1 Monohydroxy EPA
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Despite the explored potential of EPA and EPA bioactives in human physiology,
inflammation, infection, injury models, and cardiac disorders, the biological conversion of
EPA from ALA remains unrealible and severely restricted. Overall, only 6% of dietary ALA
is converted to active EPA, and a high intake of omega-6 fatty acids decreases this to 2.4%–
3% (Gerster, 1998). Furthermore, EPA undergoes a series of metabolic degradation under
the regulation of various LOXs to produce bioactive lipid mediators in response to stress,
i.e., exercise, injury or infection. COX-2 and/or aspirin or cytochrome p450 induced EPA
oxidative catalysis and resulted in 18-HEPE via an intermediate 18-HpEPE (Serhan and
Petasis, 2011). 5-LOX and 15-LOX possess an affinity for 18-HEPE and catalase production
of resolvin (RvE1 and RvE2 by 5-LOX; RvE3 by 15-LOX) (Oh et al., 2011). It has been
established that RvEs regulate immune cell trafficking and promote the resolution of
inflammation in a variety of murine translational models.
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Recently, a few more EPA metabolites, including 5 hydroxyeicosapentaenoic acids (HEPE),
8-HEPE, 9-HEPE, 12-HEPE and 18-HEPE (hydroxylation products of EPA) were tested in
many experimental models and reported distinct pharmacological properties (Calviello et al.,
2013). E-series resolvins modulate peroxisome-proliferator-activated receptors (PPARs) and
represent a class of the nuclear receptor superfamily associated with fatty acid storage and
their catabolism. Yamada et al. have demonstrated the role of EPA in up-regulation of
PPARs and the subsequent catabolism of fatty acids in 3T3-F442A, NIH-3T3, and C2C12
cell cultures (Yamada et al., 2014). Furthermore, HEPEs also control endometriotic lesion
development, but the complete physiological functions of HEPEs are yet to be explored
(Tomio et al., 2013). With the advancement of mass spectrometry technology and the
structural elucidation effort from the Serhan laboratory, EPA and EPA-derived lipid
mediators remain ideal candidates to be studied for the resolution of inflammation (Dalli et
al., 2018; Serhan, 2014). However, these omega-3 fatty acid derivatives have shown a
significant variation in their pharmacology. Nording et al., found individual responsiveness
to omega-3 fatty acids in healthy individuals is greatly variable and measurable, and this can
be used as a marker for disease risk and determining metabolic phenotype (Nording et al.,
2013). Additionally, 18-HEPE, an EPA (omega-3 fatty acid) metabolite, has shown to be
effective in limiting cardiac remodeling. Use of fat-1 mice allowed the investigation of 18HEPE and its reduction of macrophage-mediated pro-inflamamtory activation of cardiac
fibroblasts in a murine model of hypertrophy. The study has revealed the EPA, and 18-HEPE
are beneficial, not only for inhibiting fibrosis in cardiac tissue but also for improving cardiac
function (Endo et al., 2014). Administration of 18-HEPE to mice prevented pressureoverload-induced cardiac fibrosis and inflammation. These findings support previous studies
carried out by Tavazzi et al. and Yokoyama et al. (Tavazzi et al., 2008; Yokoyama et al.,
2007). These studies aimed to investigate the effect of a fish diet on prevention of major
coronary events in hypercholesterolaemic individuals. These two studies were carried out
using randomized clinical trials with dietary supplementation of omega-3 PUFAs and
protective role in atherothrombotic cardiovascular disease, including arrhythmias (Tavazzi et
al., 2008; Yokoyama et al., 2007). Patients supplemented with omega-3 fatty acids had
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improved cardiac function and reduced mortality due to chronic heart failure. Furthermore,
Nodari et al. demonstrated that omega-3 fatty acids improve left ventricular functional
capacity and decrease the circulating concentrations of inflammatory cytokines such as
TNF-α and IL-6 in non-ischemic dilated cardiomyopathy (Nodari et al., 2011). The
bioactive lipid mediators derived from EPA metabolism were reported as having several
other physiological functions such as pro-inflammatory signaling and neuroprotection in
addition to the resolution of inflammation (Bazan, 2007). The PGE3 derived from the COXmediated metabolism of eicosapentaenoic acid (EPA) reduces angiogenesis, cell
proliferation and cell invasion (Connolly, 1999). These activities suggest that PGE3 plays a
role in the protection against cancer development and its metastasis (Yang et al., 2014). It
has also been reported that the EPA-derived lipid mediator PGJ3 helps in fighting against
leukemia (Weylandt et al., 2015). There has been increasing belief that omega-3 PUFAs and
their metabolites can result in the development of new generation anti-tumor drugs (Azrad et
al., 2013). The lipid signaling plays an important role in tumor development and
downregulation, resulting in expression of pro-inflammatory and pro-tumorigenic
eicosanoids from ARA in the tumor microenvironment (Wanga et al., 2014). These findings
suggested that eicosanoid metabolism and subsequent inhibition of prostaglandin E2 (PGE2)
production contribute to EPA-elicited anti-proliferative activity in various cancers. Recent
research shows that the lipid signaling is dysregulated in tumor tissues, leading to increased
production of pro-inflammatory and pro-tumorigenic eicosanoids from ARA in the tumor
microenvironment (Kang, 2013). The over activity of ARA-derived mediators leads to upregulation of pro-tumorigenic lipid- metabolizing enzymes, including COX-2, 5-LOX and
CYP epoxygenases, as well as down-regulation of anti-tumorigenic enzyme 15-LOX1
(Zhang, G. et al., 2014). These modifications at the gene level provide a supportive
microenvironment for tumor development and progression. Both EPA and DHA were
reported having an inhibitory effect in the ARA-derived 6-series lipid mediators via multiple
mechanisms, including the reduced release of ARA from membrane phospholipids,
inhibition of the enzymatic activities of the metabolizing enzymes, and direct competition
with ARA for the enzymatic conversions (Shao et al., 2014). The bioactive lipid mediators
produced under the activities of COX-2, LOX, and CYP were reported to have strong antitumorigenic activities (Qian and Xu, 2014). Recent findings suggest that omega-3 fatty acids
possess the potential for controlling type 2 diabetes (T2D) in addition to its anti-tumor
property. A random clinical trial study carried out in 2010 by Suzanne Hendrich suggested a
dietary intake of omega-3 fatty acids, both DHA and EPA, improves plasma triglycerides in
human clinical studies of people with T2D (Hendrich, 2010).
10.2 Resolvin E1
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The RvE1 (5S,12R,18R-trihydroxyeicosapentaenoic acid) is derived from the oxygenation
of EPA (Endo et al., 2014). There is significantly growing interest in EPA-derived
molecules, also E-series resolvin, to explore their therapeutic potential in the eye, lung, and
periodontal disease pathologies (Table 3) (Cianci et al., 2016; Croasdell et al., 2015;
Hasturk, H. et al., 2007; Hodges et al., 2017; Lee et al., 2015). Many E-series resolvins act
within a local inflammatory milieu to stop leukocyte recruitment and promote resolution
(Arita, 2012). RvE1 possesses broad substrate affinity and executes actions by regulating
and/or inhibiting many pathways. In the course of resolution of inflammation, RvE1
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mediates its action by blocking PMN transendothelial migration and facilitating apical PMN
clearance from mucosal epithelial cells (Serhan et al., 2000). Furthermore, RvE1 also
inhibits NF-κβ activation, a central pathway that links various inflammation signaling by
LTB4-BLT1 attenuation result in inhibition of superoxide species (Arita et al., 2007;
Campbell EL, 2007). Stereoselective biosynthesis suggested that RvE1 (RvE1; (5S, 12R,
18R)-trihydroxy-6Z, 8E, 10E, 14Z, 16E-eicosapentaenoic acid) is an oxygenase product
with diverse biological activity (Oh et al., 2011). RvE1 is tested in reperfusion injury using
open-chest rat model of ischemia-reperfusion. The cardioprotective action of RvE1 was
reported to be quite different from other resolvin and protectins. In the study of H9c2 cell
line, it is shown that RvE1 acts directly on cardiomyocyte (Figure 6 showing multiple
activity of RvE1) (Arita et al., 2005; Dona et al., 2008; Fredman et al., 2010; Freire et al.,
2017; Hasturk, H. et al., 2007; Haworth et al., 2008; Ishida et al., 2010; Keyes et al., 2010;
Lee et al., 2016; Li et al., 2010; Schwab et al., 2007). RvE1 offers protection in reperfusion
injury by limiting leukocyte diapedesis (Serhan et al., 2008). Additionally, RvE1 attenuates
caspase-3 activity along with Bax and Bcl-2 in the rat model of chronic inflammation
(carrageenan-sponge implant model) (El Kebir and Filep, 2013). In addition to offering
cardiac protection, RvE1 was reported beneficial in inhibition of corneal inflammation. In
addition, RvE1 is effective in lipopolysaccharides (LPS), antibiotic-killed Pseudomonas
aeruginosa and Staphylococcus aureus-induced inflammation in C57BL/6 mouse corneas.
Results have shown a complete inhibition of cytokine production in C57BL/6 mouse
corneas, which provides evidence for an anti-inflammatory effect on human corneal
epithelial cells (Ma et al., 2015). In addition to above-mentioned effects, RvE1 also
indicated to improve wound healing without apoptosis of corneal epithelial cells (Hasturk,
Hatice et al., 2007; Serhan, 2009). EPA plays an important role in the regulation of serum
glucose levels and E-series resolvins to offer protection against diabetes (Boden and
Shulman, 2002; Jump, 2011). In recent findings, RvE1 is effective in rescuing impaired
neutrophil phagocytosis in T2D (Herrera et al., 2015). RvE1 was reported to enhance
neutrophil phagocytosis in obese T2D mice overexpressing human RvE1 receptor. Some
reports suggest that EPA as omega-3 fatty acid reduces hypersensitivity and asthmatic
complications. Hiram et al. investigated the beneficial role of RvE1, which is resolving
human arterial hyperactivity via the resolution of inflammatory markers (Hiram et al., 2015).
Furthermore, RvE1 inhibits dendritic cell migration in the skin and attenuates contact
hypersensitivity responses, which provides clear evidence of combating allergic
complications (Flesher et al., 2014; Hisada et al., 2009). RvE1 was also reported to attenuate
T cell priming in the draining lymph nodes and effector T cell activation in the skin, which
led to reduced skin inflammation (Sawada et al., 2015).
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10.3 Resolvin E2
RvE2; a 5S,18-dihydroxy-eicosapentaenoic is a new addition to the E-series resolvin family
(de Souza et al., 2006). Bioactive lipid mediator RvE2 (RvE2) was identified with antiinflammatory and pro-resolving activity via inhibiting PMN leukocyte infiltration. RvE2
mediates increased production of anti-inflammatory cytokines and inhibits the synthesis of
IL-1, TNF- α, and other major pro-inflammatory cytokines in order to help in tissue
homeostasis during resolution of inflammation (Locke et al., 2015). Now it is confirmed that
human recombinant 5-LOX generates RvE2 from EPA and a common precursor of E-series
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resolvins, namely, 18-HEPE possesses similar biological activity (Tjonahen et al., 2006).
Recently, the complete structure of RvE2 was confirmed by using total organic synthesis
(Ogawa S, 2009). Sungwhan et. al., reported leukocyte-directed actions of RvE2 as one of
the local mediators of tissue homeostasis during inflammation resolution (Oh et al., 2012). A
study using human PMNs provided clear evidence that RvE2 mediates resolution of
inflammation via leukocyte G-protein-coupled receptors (R-23), activating chemotaxis of
human neutrophils, phagocytosis and anti-inflammatory cytokine production (Oh et al.,
2012)
10.4 Resolvin E3

Author Manuscript
Author Manuscript

The physiological functions of RvE1 and RvE2, both of which are biosynthesized by
neutrophils via the 5LOX pathway, have been studied in the last few years (N., 2007). A
recent addition is a novel E-series resolving 17,18 dihydroxyeicosapentaenoic acid (17, 18
diHEPE) with enhanced pro-resolving activity (Isobe et al., 2012). In addition to 17,18diHEPE, a few more bioactive lipid mediators intermediates were reported, including 8, 18
dihydroxyeicosapentaenoic acid (8,18 diHEPE); 11,18-diHEPE; and 12,18-diHEPE from
18-HEPE (Schneider et al., 2007). 8,18 diHEPE is involved in the overexpression of GAL4PPARα, GAL4-PPARγ, and GAL4-PPARδ. The PPARs are a member of nuclear receptor
family and are involved in regulation and storage of lipids. Further, 11/18- and 12/18diHEPE are reported to reduce pplatelet aggregation and 5-HT release, while increasing cell
membrane fluidity and neuroprotection respectively (Buckley et al., 2014). The 5-LOXs
mediate biosynthesis of RvE1 and RvE2 in neutrophils, while 12/15-LOXs catalyze the
biosynthesis of RvE3 in eosinophils (Gronert et al., 2005). The unique nature of LOXs
strongly suggests catalytic promiscuity in enzymes associated with lipid mediators
biosynthesis. 5-LOX and 15-LOX show broad affinity to 18-HpEPE to biosynthesize
different HpEPEs. Scientific reports also provide clear evidence that RvE3 plays an essential
role in maintaining renal functions by regulating oxidative damage and lipid peroxide
activity. A recent report suggests that there is a decrease in eicosanoids and docosanoids
metabolite levels after oral administration of a higher dose of arachidonic acid (Katakura et
al., 2015). The decrease in plasma level of eicosanoids and docosanoids metabolites is due
to change in ROS and lipid peroxide after long-term use of arachidonic acid. The study
provides substantial evidence for the beneficial role of EPA-derived lipid mediators for the
resolution of inflammation (Powell et al., 1995).

11. Classical examples for other fatty acids for FADD
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Similar to DHA and EPA, α-linoleic acid and AA are transformed into numerous bioactive
lipid species. It is important to study when and where these metabolites are formed and how
they relate to physiology, disease pathology, and/or resolution of inflammation (Halade and
Kain, 2017; Kain and Halade, 2017). DHA is transformed to monohydroxy DHA, D-series
resolvins, protectins and maresins. EPA is transformed to many HEPE molecules (5-, 8-, 9-,
11-, 12-, 18-HEPE), RvE1, RvE2, and RvE3 (Endo et al., 2014). Similarly, AA, EPA, and
DHA act as precursors to cyp450 epoxygenase that lead to a generation of different EETs
(Oni-Orisan et al., 2015). Our current review is exclusively focused on the metabolic
transformation of DHA and EPA to diverse molecules with significant biological action in
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disease pathology, specifically to resolve inflammation. With the advancement of mass
spectrometry technology, other fatty acid biomolecules, such as hydroxy fatty acids (HFA)
have recently been added as new entries to lipid signaling (Dalli et al., 2018; Yore et al.,
2014). In white adipose tissue, FAHFAs are synthesized in response to signals from
carbohydrate-responsive element-binding protein (ChREBP) and streamed into circulation to
promote insulin release and glucose uptake (Yore et al., 2014). Furthermore, nitro fatty acids
(e.g., nitro -oleaic acid, -linoleic and -conjugated linoleic acid) (Delmastro-Greenwood et
al., 2015; Halade et al., 2009, 2010b; Halade et al., 2011b; Woodcock et al., 2018) and
omega-6 derived endocannabinoids (Alvheim et al., 2012) are other biomolecules that
qualify for FADD and biological action to maintain homeostatic physiology and disease
pathology. This presented approach can be used for other fatty acids, including short and
medium chain fatty acids, saturated fatty acids and different highly unsaturated fatty acids.
Application of mass spectrometry, the detection and profiling challenge has been crossed, as
now many lipid biomolecules can be measured in biospecimens, including breath
(Lundstrom et al., 2011). Future challenges include integrating the action of these local
producing autocoids, lipid mediators, eicosanoids or local hormones in response to a diverse
array of enzymes and receptors in disease pathology, inflammation, and injury.
Simultaneously, the enormous contribution of 100 trillion catalytic microbiome flora and the
influence of short and medium chain fatty acids (e.g., caprylic acid, capric acid, butyric acid,
valeric acid, etc.) need to be considered for the modification and formation of these
mediators at the physiological level in healthy subjects.

12. Pitfalls of old and current novel technologies
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Lipidome represents all molecules including lipids, fatty acids, and their metabolites, all
which possess great structural diversity and complexity (Han, 2016). The association of fatty
acids and their metabolic products (lipid mediators) in human diseases have remained
unknown for a long time, but lipid profiling remains limited due to lack of cutting-edge
quantitative technology in lipidomics. It is important to note here, the lipidome of an
organism, tissue, and cells varies in healthy and pathological conditions (Hadj Ahmed et al.,
2017). Further, there is organ/tissue- specific variation in fatty acids and variation in the
associated metabolite profile in many diseases including cardiac disorders, inflammation,
neurological and other metabolic disorders (Siguel and Lerman). Some reports in literature
measure lipids with direct infusion of the sample to mass spectrometry without
chromatographic separation of lipid biomolecules. Lipid measurements largely rely on
chromatographic separation of lipids, fatty acids, and associated metabolites using mass
spectrometry. Now the lipids field is developing (LIPID MAPS) to drive the lipidome
databases similar to proteome, though it has been quite challenging to profile a novel
bioactive(s) and associated metabolites. Advancement in the analytical techniques such as
MS-based technologies (MALDI-TOF, MALDI-MS/MS, and LCMS/MS, MS-based
bioactive lipid imaging) have merged to advance lipidome studies, but at the same time,
there is need to understand the mechanism of lipids in systems biology (Halade and Kain,
2017; Junot et al., 2014; Ma et al., 2015). There have been difficulties to determine the
trafficking of lipids, fatty acids, and associated metabolites as all of these molecules are
complex to tag with reporter molecules unless it is conjugated with a protein and/or
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chemical (fluorescent tagging) (Schultz et al., 2010). Radiolabeled lipids, fatty acids, and
associated metabolites remain a primary option in early days of lipid profiling,
quantification, and localization (Wakabayashi et al., 1994). Similar to other biomolecules,
including nucleic acids and proteins (via mutational analysis), lipids and fatty acids are
difficult to modify to study their physiological significance. Hence, a novel approach is
essential to study the metabolic transformation of fatty acid to bioactive lipid mediators
involved in diseases (pro-inflammatory) or reparative mechanisms to resolve inflammation
(anti-inflammatory).

13 Future prospective on DHA and EPA metabolites and their mechanism of
action
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Author Manuscript

Traditionally, lipids were considered energy sources with powerful brick and mortar capacity
that separates the interior cell cytoplasm from the external stress or injury. Lipids are
building blocks of cell membrane components and, in response to external stimuli, fatty
acids breakdown in to endogenous molecules to be involved various signalling processes and
regulate different physiological events (Glatz, 2011). At this time, there has been an
increasing emphasis on studying fatty acids and their associated metabolites for their
therapeutic applications. Despite dynamic efforts, the molecular characterization of
biomolecules remains difficult in context with physiological events as these molecules
require meticulous sample preparation and prudent extraction methodology (Dalli et al.,
2018; DH, 2003). The major point of FADD is translational and has direct relation to
enzymes (LOXs and COXs), thus providing the opportunity for prognostic, personalized,
and precise medical discovery. It remains a major challenge to study affinity of fatty acids
with metabolizing enzymes and the rate-limiting step in metabolic events. With the
emerging, cutting-edge quantitative lipidomics and proteomics offer the ability to determine
the lipidome of a cells and even whole organisms (Tumanov and Kamphorst, 2017). Based
on chemical structural resemblance to FADD biomolecules, the development of new
mimetics is emerging as an approach to study binding affinity and feed-forward activation or
suppression of metabolizing enzymes (Proschak et al., 2017). Indeed, we offer a list of
efforts that are imperative for advancing the field of fatty acid research and subsequent
FADD:
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1.

Stability of DHA and EPA metabolites (monohydroxy DHA/EPA, resolvins,
maresins and protectins) in healing and non-healing inflamed organs, milieu, or
biological compartments

2.

Optimal requirement of fatty acids substrates DHA and EPA and check point to
ensure presence of LOX enzyme to metabolize the substrate

3.

Supply of dietary DHA and EPA to feed LOX enzymes for metabolic
transformation into biomolecules in response to injury or infection

4.

Lipids trafficking in response to injury, infection, exercise or aging

5.

Organ-specific verses immune-cell-specific receptor(s) to initiate
pharmacological action
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6.

Impact of pro-inflammatory molecules like leukotrienes and prostaglandins in
receptor sensitization or desensitization with lower levels of DHA and EPA

7.

Identification and validation of novel and functional sensor for monohydroxy
DHA and EPA, D- and E-series resolvins, maresin and protectins

14. Conclusion
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With the advancement of lipidomics technology and an enormous contribution from the
Serhan laboratory and others in structural elucidation, much progress has been made to
capitalize the molecular and cellular signaling of DHA and EPA biomolecules in disease
pathology. Thus, DHA and EPA transformation to a number of lipid biomolecules
exemplifies the successful launching of Fatty Acid Drug Discovery (FADD). The emphasis
on lipid absorption, distribution, storage, metabolism and excretion (dietokinetics or
nutrikinetics) from birth to aging, as well as lipid utilization (nutridynamics or
dietodynamics), will be an active an area of research for novel biomolecules. In the area of
personalized and precise medicine, it is important to personalize diet to precisely treat
infection and injury based on age (infant, teen, adult, aging or senescent) as well as average
energy expenditure. What is unclear at this point is how drug treatment, aging, and other
factors (diet, microbiome, or epigenetics) decrease omega 3 (DHA and EPA) storage and
metabolism to form different lipid mediators. DHA- and EPA-derived pro-resolving lipid
mediators could have undetected levels or could be lowered as a result of stress due to
senescent pathophysiology. In addition, the pro-inflammatory burden in obese subjects could
also contribute to decreased metabolism and use of DHA and EPA-derived lipid mediators.
This defect may be at the enzymatic level (low LOX and COX activity) or substrate level
(low DHA and EPA levels), but future studies of novel DHA- and EPA-derived
immunoresolvents such as resolvins, lipoxins maresins, and protectins will provide a
foundation to make progress in resolution pharmacology and physiology. Thus, novel
approaches can be used to potentiate the action of DHA and EPA biomolecules using the
FADD approach in the lipid world.
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AA

Arachidonic acid

ALA

α-linolenic acid

ChREBP

carbohydrate responsive element-binding protein

COX

Cyclooxygenase

CVD

Cardiovascular disease

CYP

Cytochrome p450
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D5D

Delta-5 desaturase

D6D

Delta-6-desaturase

DHA

Docosahexaenoic acid

EPA

Eicosapentaenoic Acids

FABP

Fatty acid binding protein

FADD

Fatty acid drug discovery

FADS

Fatty acid desaturase

HETE

Hydroxy eicosatetraenoic acid

HODE

Hydroxy octadecadienoic acid

HPETE

Hydroperoxy eicosatetraenoic acid

IL

Interleukin

IPE

Icosapent ethyl

LA

Linoleic acid

LOX

Lipoxygenase

LPS

Lipopolysaccharides

LTs

Leukotrienes

LXs

Lipoxins

MI

Myocardial infarction

NF-κβ

Nuclear factor kappa β

NIH

National Institutes of Health

NO

Nitric oxide

PGs

Prostaglandins

PI3K/Akt

Phosphoinositide 3-kinase/protein kinase

PMNs

Polymorphonuclear leukocytes

PUFA

Polyunsaturated fatty acid

SCD

Stearoyl-CoA desaturase

SPM

Specialized pro-resolving mediators

T2D

Type 2 diabetes

TNF

Tumor necrosis factor
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Figure 1. Process for Fatty Acid Drug Discovery (FADD) approach

Illustration depicts the processes of traditional versus reverse pharmacology. Using fatty
acids as drug biosynthesizing candidates, reverse pharmacology is a feasible, more costeffective method to develop novel molecules to combat diseases associated with conditions
such as aging, inflammation, injury, and infection. eicosapentaenoic acid (EPA);
docosahexaenoic acid (DHA)
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Metabolism of omega-3 and omega-6 dietary fatty acids and respective lipid mediators.
Arachidonic acid (AA); eicosapentaenoic acid (EPA); docosahexaenoic acid (DHA);
docosapentaenoic acid (DPA); 5-lipoxygenase (5-LOX); 12-lipoxygenase (12-LOX); 15lipoxygenase (15-LOX); cyclooxygenase (COX); leukotriene (LT); lipoxin A4 (LXA4);
prostaglandins (PGs); E-series resolvins (RvEs); D-series resolvins (RvDs); 13-series
resolvins (RvTs).
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Figure 3.

Estimated chronological depiction of major points in the development of D-series resolvin
mediators controlling inflammation and promoting resolution of inflammation. Timeline
displays the estimated progression of the fish oil-enriched diet to the development of drugs
for the treatment of hyperlipidemia to the advancement of D-series mediators from DHA.
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Figure 4.

Estimated chronological depiction of major points in the development of E-series resolvin
mediators controlling inflammation and promoting resolution of inflammation. Timeline
displays the progression of the fish oil-enriched diet to the development of drugs for the
treatment of hyperlipidemia to the advancement of E-series mediators from EPA.
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Figure 5.

Sketch indicating the beneficial potential and mechanism of Resolvin D1 in resolution
pathophysiology.
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Figure 6.

Sketch indicating the beneficial potential and mechanism of Resolvin E1 in resolution
pathophysiology.
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Author Manuscript

List of common dietary fatty acids, source and physicochemical significance in the context of human
pathophysiology.

Author Manuscript

Chemical Formula

Carbon backbone and
Saturation

Physiological Significance

Source

Palmitic acid

C16H32O2

16 & Saturated

Energy source

Palm oil, meat and
dairy fats

Stearic acid

C18H36O2

18 & Saturated

Energy source

Meat fat, cocoa butter

Oleic acid

C18H34O2

18 & Monounsaturated

Blood pressure regulation

Canola oil, sunflower
oil and almond

Linoleic acid

C18H32O2

18 & Polyunsaturated

AA biosynthesis

Corn, safflower,
soyabeen and
sunflower

Linolenic acid

C18H30O2

18 & Polyunsaturated

Biosynthesis of EPA and DHA

Walnuts, Canola oil,
cotton seed and
sunflower oil

Arachidonic acid

C20H32O2

20 & Polyunsaturated

Source for inflammatory mediators
and pro- resolving lipoxins

Meat and poultry eggs

Docosahexaenoic acid

C22H32O2

22 & Polyunsaturated

Source of D-series resolvins,
protectins and maresins

Fatty fish, fish oil and
algal oil

Eicosapentaenoic acid

C20H30O2

20 & Polyunsaturated

Source of E series resolvins

Fatty fish and fish oil

Fatty Acid
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Table 2

Author Manuscript

Novel finding on RvD1 in different model of resolution pathobiology

Author Manuscript

Pathobiology mode

Mechanistic finding

Mice ischemia reperfusion – acute kidney injury
–(Duffield et al., 2006)

↓ leukocyte accumulation, ↑ activation of reparative
macrophages and ↓ interstitial fibrosis protection from ischemic
acute kidney injury

Duffield et al., 2006

Mice - diet-induced obesity- murine (Titos et al.,
2011)

↓ Th1 cytokines, ↑ macrophage arginase-1 and other M2 marker
expression

Titos et al., 2011

Mice - type 2 diabetes- murine (Tang et al.,
2013)

↑ resolution of peritonitis, ↓ apoptotic thymocytes and ↑
macrophage phagocytosis

Tang et al., 2013

Mice - ischemia reperfusion (Shinohara et al.,
2014)

↓ polymorphonuclear leukocyte lung infiltration and platelet
aggregates
↓ leukotrienes and thromboxane B2

Mice - corneal allotransplantation – (Hua et al.,
2014)

↓ dendritic cell maturation, ↑corneal allograft survival and ↓ host
T-cell infiltration and corneal angiogenesis

Hua et al., 2014

Mice - myocardial infarction (Kain et al., 2015)

↑ fractional shortening, ↓ left ventricular hypertrophy, ↓
pulmonary edema, ↑ clearance of macrophages and neutrophils
post-injury, and ↑ inflammation resolution

Kain et al., 2015

Mice - ischemia/reperfusion liver injury (Kang
and Lee, 2016)

↓ myeloperoxidase activity and Cxcl1 and Cxcl2 mRNA
expression and ↑ M2 polarization

Kang et al., 2016

Mice - rheumatoid arthritis (Norling et al., 2016)

↓ arthritis severity, cachexia, hind-paw edema, and paw
leukocyte infiltration

Norling et al., 2017
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Table 3

Author Manuscript

Novel finding of RvE1 in different model of resolution pathophysiology

Author Manuscript

Pathobiology model

Mechanistic finding

Female BALBc and male FVB mice – peritonitis colitis
(Arita et al., 2005)

protection of intestinal inflammation and ↓ colitis

New Zealand White rabbits - periodontal disease (Hasturk H,
2007)

↓ systemic inflammation and ↓ C-reactive protein and
IL-1beta

Platelet-rich plasm and human blood – platelet activation
(Dona et al., 2008)

↓ leukocyte rolling ↓ ADP-induced platelet
aggregation

FVB mice – lung injury (Haworth et al., 2008)

↓ IL-23 and IL-6 ↑ resolution of allergic airway
inflammation

Haworth et al., 2008

Human platelet – platelet activation (Fredman et al., 2010)

↓ ADP-stimulated P-selectin mobilization and actin
polymerization

Fredman et al., 2010

Male C57BL/6J mice – lung injury (Seki et al., 2010)

↓ bacterial infection and acute lung injury

Female C57BL/6 mice – dextran-induced colitis (Ishida et
al., 2010)

↓ pro-inflammatory responses of macrophages

Dry eye mouse model (Li et al., 2010)

↑ tear production, ↓ inflammation, and ↓ inducible
COX-2

Li et al., 2010

Female BALB/c mice – pulmonary inflammation (El Kebir
and Filep, 2013)

↑ neutrophil apoptosis and ↑ activation of caspase 3
and 8

Kebir et al., 2012

Mice - LPS, P. aeruginosa and S. aureus infection (Lee et al.,
2015)

↓ corneal Inflammation

Lee et. al., 2015

Rats – periodontitis and dysbiosis (Lee et al., 2016)

↓ bone loss, ↓ inflammatory gene expression, and ↓
osteoclast density

Lee et al., 2016

Human - neutrophils and monocyte/macrophages- (Freire et
al., 2017)

RvE1 receptor leukotriene B4 (BLT-1) on neutrophils
ERV-1/ChemR23 on monocyte/macrophages

Author Manuscript
Author Manuscript
Biotechnol Adv. Author manuscript; available in PMC 2019 July 01.

Reference
Arita et al., 2005
Hasturk et al., 2007
Dona et al., 2008

Seki et al., 2010
Ishida et al., 2010

Freire et al., 2017

